High probability seasonal trading setup for BioLife Solutions Inc.(BLFS).
Holding BioLife Solutions Inc.(BLFS) for 46 days from 2021-04-19 to 2021-06-04 for the last 20 years yielded an Average return of 16.34%. over these years, 15 years were positive. Holding BLFS for 46 days each year for the last 20 years yielded a total net profit of 963.48%.
Investment Strategy Simulated Trading Results
|Entry Date||Entry Price||Exit Date||Exit Price||Return|
|Apr 20, 2020||10.51||Jun 4, 2020||15.85||50.81%|
|Apr 22, 2019||16.26||Jun 4, 2019||18.74||15.25%|
|Apr 19, 2018||7.33||Jun 4, 2018||10.37||41.47%|
|Apr 19, 2017||2.05||Jun 5, 2017||2.16||5.37%|
|Apr 19, 2016||1.90||Jun 6, 2016||1.60||-15.79%|
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Industry: Medical Instruments & Supplies
|Dividend Per Share||None|
|Quarterly Earnings Growth YOY||6.40|
|Quarterly Revenue Growth YOY||0.78|
|Analyst Target Price||56.25|
|Price To Sales Ratio TTM||20.44|
|Price To Book Ratio||5.86|
|EV To Revenue||23.36|
|EV To EBITDA||647.00|
|Exit Dividend Date||None|
|Fiscal Date Ending||Reported Date||Reported EPS||Estimated EPS||surprise||Surprise Percentage|